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Abstract Matrix metalloproteinases (MMPs) are secreted
endopeptidases that play an essential role in remodeling
the extracellular matrix (ECM). MMPs are primarily active
during development, when the majority of ECM remodeling
events occurs. In adults, elevated MMP activity has been
observed in many pathological conditions such as cancer
and osteoarthritis. The proteolytic activity of MMPs is controlled by their natural inhibitors - the tissue inhibitor of
metalloproteinases (TIMPs). In addition to blocking MMPmediated proteolysis, TIMPs have a number of MMPindependent functions including binding to cell surface proteins thereby stimulating signaling cascades. TIMP-2, the
most studied member of the family, can both inhibit and
activate MMPs directly, as well as inhibit MMP activity
indirectly by upregulating expression of RECK, a membrane anchored MMP regulator. While TIMP-2 has been
shown to play important roles in breast cancer, we describe
how the MMP-independent effects of TIMP-2 can modulate
the invasiveness of MCF-7, T47D and MDA-MB-231
breast cancer cells. Using an ALA + TIMP-2 mutant which
is devoid of MMP inhibition, but still capable of initiating
specific cell signaling cascades, we show that TIMP-2 can
differentially affect MMP activity and cellular invasiveness
in both an MMP dependent and independent manner. More
specifically, MMP activity and invasiveness is increased
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with the addition of exogenous TIMP-2 in poorly invasive
cell lines whereas it is decreased in highly invasive cells
lines (MDA-MB-231). Conversely, the addition of ALA +
TIMP-2 resulted in decreased invasiveness regardless of cell
line.
Keywords TIMP . MMP proteolysis . MCF-7 . T47D .
MDA-MB-231 . Breast cancer
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Introduction
The extracellular matrix (ECM) is a dynamic network of
interacting macromolecules whose components mediate cell
behavior by creating influential cellular environments. The
turnover and remodeling of the ECM is an integral part of
normal and pathological processes such as development,
cell growth, differentiation, and metastasis (Lambert et al.
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2004). ECM remodeling is predominantly accomplished by
a family of proteins known as matrix metalloproteinases
(MMPs) (Ra and Parks 2007). MMPs consist of 24 proteins
that collectively cleave all components of the ECM. Although the role of MMPs was traditionally thought to be
restricted to catabolism of structural ECM components,
there is a growing consensus that the role of MMPs is much
broader. (Mott and Werb 2004; Walsh and Damjanovski
2011) Some established functions for MMPs now include
the release of sequestered growth factors, cleavage of
growth factor receptors from the cell surface, shedding of
cell adhesion molecules, and the activation of other MMPs
(Gill et al. 2010).
To avoid excessive proteolysis and tissue damage, the
activity of MMPs is carefully regulated in a number of
different ways. One regulatory mechanism is the proteolytic
inhibition of MMPs by tissue inhibitors of metalloproteinases (TIMPs) (Zucker et al. 1998). The human TIMP
family consists of four members, designated TIMP-1,-2, 3, and -4, that can bind to and directly inhibit the catalytic
activity of MMPs (Lambert et al. 2003). Although TIMPs
were originally characterized as proteolytic inhibitors of
MMPs, it has been shown that TIMPs are multifaceted proteins capable of MMP- independent functions. TIMP-2 is of
particular interest because it is the most extensively studied
TIMP both in disease and development (Stetler-Stevenson
2008; Walsh et al. 2007). There are two known MMP dependent functions of TIMP-2. The first is binding and inhibiting
the proteolytic activity of MMPs, while paradoxically the
second is the activation of proMMP-2 (Seo et al. 2003). All
MMPs are translated as inactive zymogens and as such, require activation through cleavage of a pro-domain (Ra and
Parks 2007). TIMP-2 aids in the activation of proMMP-2 by
binding and association with two MMP-14 proteases at the
cell surface that cleave the pro-domain of MMP-2 and release
it into the ECM in its active form (Yana and Seiki 2002).
TIMP inhibition of MMPs occurs through the TIMP Nterminal domain. TIMP functions that are independent of
MMP binding are poorly understood although there is evidence they involve the C-terminal of the TIMP molecule.
The C-terminal domain of TIMP-2 has been shown to bind
to cell-surface α3β1 integrin (Seo et al. 2003). Binding to
this integrin induces a signaling cascade that results in the
regulation of growth, and upregulation of RECK (‘reversion-inducing-cysteine-rich protein with kazal motifs’) (Oh
et al. 2004). The RECK gene codes for a membrane bound
MMP regulator that can inhibit MMP activity in three ways:
direct inhibition of the proteolytic activity of MMP-2, -9,
and -14; inhibition of proMMP-2 activation by preventing
proMMP-2/TIMP-2/MMP-14 complex formation; and by
inhibiting the secretion of MMP-9 (Rhee and Coussens
2002). It has been shown in numerous studies that RECK
expression is downregulated in various human cancers and
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that high RECK expression is correlated with a positive
prognosis and increased patient survival (Noda & Takahashi,
2007). This also correlates with the finding that RECK mRNA
is expressed ubiquitously in normal human tissue, while it is
undetectable in a number of tumour-derived cell lines (Rhee &
Coussens, 2002). Interestingly, these cell lines showed reduced tumour angiogenesis, invasion and metastasis when
stably transfected with RECK.
The balance between MMPs and TIMPs in cancer progression has recently received considerable attention as
these two protein families are implicated as important regulators of several key steps in carcinogenesis (StetlerStevenson and Seo 2005). By virtue of their activity,
MMPs are most closely associated with the invasive and
metastatic aspect of cancer progression, as increased MMP
activity allows cancer cells to invade through the ECM and
metastasize into other tissues (Zhang et al. 2006). MMPs are
overexpressed in almost all human cancers and high MMP
expression usually correlates with a poor prognosis (Rhee and
Coussens 2002). Accordingly, an attempt was made to create
synthetic MMP inhibitors as a cancer therapy. However,
clinical trials of these synthetic MMP inhibitors did not
produce significant results for reasons not yet understood (Stetler-Stevenson 2008). The failure of synthetic
MMP inhibitors as a cancer therapy, along with the
many roles of TIMP-2, highlights that our understanding
of TIMP and MMP biology is incomplete and more
complicated than initially thought (Dove 2002). The intricacy
of MMP/TIMP interactions, complicated by the possible role
of molecules such as RECK, has made understanding the
regulation of matrix remodeling difficult as the relative roles
and expression levels of these and other molecules likely
varies between cell types.
The purpose of this study is to further understand the
dynamic relationship between TIMP-2 and MMPs by treating
breast cancer cells with conditioned media containing high
levels of exogenous TIMP-2 or ALA + TIMP-2. ALA +
TIMP-2 is a TIMP-2 mutant containing an additional amino
terminal alanine, which renders it unable to inhibit MMPs
(Wingfield et al. 1999). As such, while ALA + TIMP-2 cannot
inhibit MMPs directly, or activate proMMPs, it is still capable
of binding to cell surface receptors, such as α3β1 integrin, and
inducing integrin signaling (Seo et al. 2003). Here we show
that treatment of breast cancer cells lines with ALA + TIMP-2
resulted in decreased invasiveness concomitant with decreased MMP activity regardless of cell line. Interestingly,
wild-type TIMP-2 treatment resulted in opposing effects
depending on the aggressiveness of the cell line. Noninvasive
cells revealed increased MMP activity and increased invasiveness after treatment, while invasive cells revealed the opposite. Accordingly we propose the TIMP-2 activation/
inhibition activity may be dependent on endogenous levels
of MMPs.

Analysis of the MMP-dependent and independent functions of tissue

Materials and methods
Kaplan-Meier analysis
An available DNA microarray database (van 't Veer et al.
2002) from the analysis of tumors of 117 young patients
whose prognosis and outcome were correlated to specific
genes signatures, was used to examine the relationship between TIMP-2 expression and survival in breast cancer
patients. Patients whose TIMP-2 expression levels were
within one standard deviation of the mean were removed.
The remaining data points were designated as either “0” for
low expressors, or “1” for high expressors. Invariant analysis of survival was estimated by the Kaplan-Meier method
(using SPPS software) and compared using the log rank test.
Analysis was performed to examine the relationship between low “0”, and high “1”, TIMP-2 expression and
metastasis-free survival (Fig. 1a), as well as overall patient
survival (Fig. 1b). Log rank p<0.05 was considered statistically significant.

Generation of the TIMP-2 and ALA + TIMP-2 expression
constructs
A DNA plasmid vector containing the full-length cDNA
sequence of human TIMP-2 (Origene) was used to generate
the TIMP-2 and ALA + TIMP-2 constructs. To PCR amplify the TIMP-2 cDNA, primers 20 base pairs (bp) long were
used that were complementary to the 5’ and 3’ ends of the
TIMP-2 coding region. To PCR amplify the ALA + TIMP-2
sequence from the TIMP-2 cDNA, the 3’ primer used was

Fig. 1 High tissue of inhibitor of metalloproteinases-2 (TIMP-2) expression is correlated with prolonged and metastasis-free survival in
breast cancer patients. Kaplan-Meier survival plot demonstrated that
TIMP-2 expression stratified subjects in two groups with significantly
different a metastasis-free survival or b cumulative survival after
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the same, but the 5’ primer was much longer in order to add
an alanine codon after (3’ of ) the signal sequence as TIMP2 is a secreted protein (Fig 2a). Following PCR, amplicons
were ligated in pcDNA™ 3.3 TOPO mammalian constitutive expression vectors as per kit instructions. The correct
DNA sequence was verified by the DNA Sequencing Facility at the Robarts Research Institute (The University of
Western Ontario).

MCF-7 cell transfection and conditioned media collection
MCF-7 cells were cultured in Dulbecco's Modified Eagle
Medium (DMEM) media (Invitrogen) with 10% Fetal bovine
serum (Invitrogen) and 1% Penicillin (100 U/mL) Streptomycin (100 μg/mL). Cells were passaged by disassociating them
with TrypLETM Express (Invitrogen) before they reached 80%
confluency. Cells were transfected with TIMP-2, ALA +
TIMP-2 or GFP (Control) plasmids using LipofectamineTM
2000 (Invitrogen). The cells were incubated with the lipofectamine/DNA mixture in Opti-Mem serum free media (Invitrogen) for 6 h and then switched to full growth media for 24 h to
recover. After recovery, and several washes with PBS, transfected MCF-7 cells were switched to Human Mammary Epithelial Cell (HuMEC) basal serum-free media (Invitrogen) for
24 h before conditioned media was collected. The collected
media was assayed for levels of TIMP-2 and ALA + TIMP-2
using a human TIMP-2 enzyme-linked immunosorbent assay
(ELISA) kit (R&D systems) as per kit instructions. The levels
of TIMP-2 and ALA + TIMP-2 were quantified by measuring
absorbance at 450 nm using a Molecular Devices M2E microplate reader.

diagnosis. P-values correspond to the log-rank test comparing survival
curves. Subjects with high TIMP-2 expression are in blue, and those
with the low TIMP-2 expression are in green. Values of p<0.05 are
considered significant
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Fig. 2 Schematic representation of ALA + TIMP-2 construct. a The
93 base pair primer designed to generate the ALA + TIMP-2 construct
by PCR amplification. The signal peptide sequence of TIMP-2 is
highlighted in yellow, the partial N-terminus of the protein in green,
and the added alanine codon in red. b Sequence data of the ALA +

TIMP-2 construct analyzed by NCBI BLAST. ALA + TIMP-2 (Query)
shows 100% amino acid identity with TIMP-2 (Sbjct) except for the
alanine codon, GCG, at the N-terminus (red). The signal peptide
(which is removed after secretion) is highlight in yellow and aminoterminus of the wildtype mature protein is in green

Matrigel invasion assay following treatment
with conditioned media

Gelatin zymography

The breast cancer cell lines MCF-7, T47D and MDAMB-231 were obtained from the American Type Culture Collection (ATCC) and were used in accordance
with UWO biosafety protocols. These cell lines were
chosen because of their variable expression of TIMPs,
MMPs and invasiveness (Figueira et al. 2009). Fifty
thousand untransfected cells were added per transwell
invasion chamber coated with 1 mg/ml Matrigel
(reconstituted basement membrane; BD Biosciences).
Cells were treated with conditioned media from
TIMP-2, ALA + TIMP-2, or GFP (Control) transfectants, and allowed to invade for 24 h. Transwell inserts
were subsequently fixed in methanol, stained with 1%
crystal violet and invaded cells counted. Three experimental replicates were performed and invading cell numbers
averaged.
Metalloproteinase activity assay following treatment
with conditioned media
Untransfected breast cancer cells grown for 24 h were
treated with conditioned media collected from TIMP-2,
ALA + TIMP-2, or GFP transfected MCF-7 cells. After
treatment for 24 h the media was removed from each
cell type for proteolytic analysis. The media collected
after treatments was used to assay MMP activity by
using a Mca-K-P-L-G-L-Dpa-A-R-NH2 Fluorogenic Peptide Substrate (R&D systems). Following BCA quantification to ensure equal protein levels, MMP activity was
quantified by measuring fluorescence with an excitation
at 320 nm and emission at 405 nm using a Molecular
Devices M2E microplate reader.

After treatment for 24 h the culture media was removed
from each cell type and analyzed by gelatin zymography as
described previously (Toth and Fridman 2001). Briefly,
following BCA quantification to ensure equal protein levels,
aliquots of media were loaded without reduction on a 0.1%
gelatin-10% acrylamide gels. After electrophoresis, gels
were washed with 2.5% Triton X-100 to remove SDS and
re-nature the MMP proteins in the gels. The gels were then
incubated in developing buffer for 24 h at 37°C to induce
gelatin lysis by the re-natured proteases. Areas of proteolytic
activity were visualized as clear bands after staining the gels
with Coomassie blue. Gels were visualized and photographed using Bio-Rad Quantity One 4.4.0 software.
Viability assay
The viability of cells after 24 h of TIMP-2 or ALA + TIMP2 conditioned media treatment was assayed using a DHL™
Cell Viability and Proliferation Assay Kit (Anaspec) as per
manufacturer’s instructions. Cell viability was quantified by
measuring fluorescence with an excitation at 590 nm and
emission at 530 nm using a Molecular Devices M2E microplate reader.
Statistical analysis
Statistical analyses of multiple comparisons for parametric
data were performed using a one-way ANOVA followed by
a Tukey–Kramer Comparisons Post-Hoc test. Data were
expressed as mean±S.E.M. for replicate values. Data comparisons for all experiments were considered statistically
significant at p<0.05.

Analysis of the MMP-dependent and independent functions of tissue
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Results
High levels of TIMP-2 expression are correlated
with prolonged and metastasis-free survival in breast cancer
patients
Using data available from a database generated by van 't
Veer et al. (2002) we wanted to establish the relationship
between levels of TIMP-2 expression, metastasis and patient
survival. Patients that expressed high levels of TIMP-2 had
a significantly higher rate of metastasis-free survival
(Fig. 1a). Fifty percent of low TIMP-2 expressors survived
metastasis-free at 8 months compared to 15 months for the
high TIMP-2 expressors. Similarly, patients that expressed
high levels of TIMP-2 survived significantly longer than
patients that expressed low levels of TIMP-2 (Fig. 1b).
Low TIMP-2 expressors had a cumulative survival rate
of about 50% after 10 months, while high TIMP-2
expressors had a cumulative survival rate of about 80% after
10 months.
Generation of the TIMP-2 and ALA + TIMP-2
expression constructs
Sequencing of the TIMP-2 and ALA + TIMP-2 constructs
showed 100% identity with human TIMP-2 and the additional amino-terminal alanine codon in the ALA + TIMP-2
mutant was in the correct position (Fig. 2).
Transfection of TIMP-2 and ALA + TIMP-2 expression
constructs resulted in high levels of secreted protein
To confirm that transfection of the expression constructs
resulted in the production of elevated levels of secreted
proteins, media from transfected cells was analyzed by
ELISA for TIMP-2 protein. MCF-7 cells transfected with
the TIMP-2 or ALA + TIMP-2 constructs secreted high
levels of respective proteins. GFP transfected cells showed
significantly lower (endogenous) expression of TIMP-2 as
compared to TIMP-2 or ALA + TIMP-2 transfected cells.
Based on known standards, the concentration of TIMP-2
and ALA + TIMP-2 in the respective conditioned media was
determined to be 22 ng/ml while the concentration of TIMP2 in the media from GFP transfected MCF-7 cells was
determined to be 0.1 ng/ml (Fig. 3).
TIMP-2 conditioned media increased the invasiveness
of MCF-7 cells
Untrasfected MCF-7 cells were treated with TIMP-2 or
ALA + TIMP-2 conditioned media to investigate effects
on invasiveness. MCF-7 cells treated with TIMP-2 conditioned media showed an over 100% increase in invasiveness

Fig. 3 TIMP-2 concentrations in conditioned medium isolated from
MCF-7 cells transfected with TIMP-2, ALA + TIMP-2 or GFP. a
Known concentrations of recombinant TIMP-2 were assayed using a
TIMP-2 ELISA kit and the optical density of each was plotted against
thcphe concentration of TIMP-2. b Levels of TIMP-2 in the conditioned media isolated from MCF-7 cells transfected with GFP, TIMP-2
or ALA + TIMP-2 constructs. TIMP-2 levels were determined to be
0.1, 22 and 22 ng/ml in the media from GFP, TIMP-2, or ALA +
TIMP-2 transfected cells respectively (as determined by comparing the
optical density to the standard curve)

as compared to control cells treated with conditioned media
from GFP (control) transfectants (Fig. 4). Conversely, MCF7 cells treated with ALA + TIMP-2 conditioned media
showed a 50% decrease in invasiveness compared to control
(Fig. 4). MCF-7 cells treated with TIMP-2 or ALA + TIMP2 conditioned media did not show any changes in viability
after 24 h of treatment as compared to control cells treated
with conditioned media from GFP transfectants (data not
shown).

T47D cells treated with TIMP-2 or ALA + TIMP-2
conditioned media displayed changes in invasiveness
consistent with MCF-7 cells
Given that MCF-7 cells treated with TIMP-2 conditioned
media paradoxically resulted in increased invasiveness, we
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decided to determine the effects of TIMP-2 treatment on a
similar cell line. T47D cells are an estrogen receptorpositive, low MMP expressing, and poorly invasive cell line
similar to MCF-7 cells. T47D cells treated with 22 ng/ml
TIMP-2 conditioned media did not significantly increase
their invasiveness. However, T47D cells treated with
ALA + TIMP-2 conditioned media resulted in a 66%
decrease in invasiveness (Fig. 5a-top).

T47D cells displayed changes in protease activity
when treated with TIMP-2 or ALA + TIMP-2 conditioned
media consistent with invasiveness
Fig. 4 Invasiveness of MCF-7 cells treated with elevated levels of
TIMP-2 or ALA + TIMP-2. TIMP-2 more than doubled the number of
invading cells, while ALA + TIMP-2 treatment decreased the number
of invading cells by ~50% compared to the GFP control. Invasion data
is shown as the average number of invaded cells per transwell chamber.
All data are mean±s.e.m based on 3 replicates. * represents a significant difference between the treatment and the control, while ** represents significant differences between treatments (p<0.05)

Fig. 5 Invasiveness and metalloproteinase activity of T47D and
MDA-MB-231 cells treated with TIMP-2 or ALA + TIMP-2 conditioned media. a-top) T47D cells treated with 22 ng/ml TIMP-2 conditioned media did not significantly increase invasiveness whereas T47D
cells treated with 22 ng/ml ALA + TIMP-2 resulted in a 66% decrease
in invasiveness. a-bottom) MDA-MB-231 cells treated with 22 ng/ml
TIMP-2 or ALA + TIMP-2 conditioned media resulted in a greater than
80% reductions in invasiveness compared to control. b-top) T47D
conditioned media displayed a 45% increase in metalloproteinase
activity with the addition of TIMP-2 and a 35% decrease in metalloproteinase activity with the addition of ALA + TIMP-2. b-bottom)
Decreases in MDA-MB-231 invasiveness with treatment with TIMP-2

To determine if the changes seen in invasiveness correlated
with changes in MMP activity, a broad spectrum MMP
activity assay was used with conditioned media isolated
from T47D cells treated with TIMP-2 or ALA + TIMP2
for 24 h. Interestingly, T47D conditioned media displayed a
45% increase in metalloproteinase activity with the addition

or ALA + TIMP-2 were concomitant with greater than 40% and 50%
decreases in metalloproteinase activity respectively. c Conditioned
media from control, TIMP-2 or ALA + TIMP-2 treated cells were
assayed for MMP activity using zymography. c-top) T47D conditioned
media displayed consistent levels of pro-MMP-2 regardless of treatment. c-bottom) MDA-MB-231 conditioned media displayed consistent levels of both pro-MMP-2 and pro-MMP-9, regardless of
treatment. a and b–all data are mean±s.e.m based on 3 replicates. *
represents a significant difference between the treatment and the control, while ** represents significant differences between treatments (p<
0.05). C is a representative zymography with several repeats showing
consistent levels between treatments

Analysis of the MMP-dependent and independent functions of tissue

of TIMP-2, but a 35% decrease in metalloproteinase activity
with the addition of ALA + TIMP-2 (Fig. 5b-top).
MDA-MB-231 breast cancer cells decreased in invasiveness
and protease activity when treated with TIMP-2 conditioned
media
Contrasting MCF-7 and T47D cells, MDA-MB-231 cells
are estrogen receptor-negative, highly invasive and secrete
elevated levels of MMPs. When treated with 22 ng/ml
TIMP-2 conditioned media, MDA-MB-231 cells displayed
a greater than 80% reduction in invasiveness compared to
control (Fig. 5a-bottom). This reduction in invasiveness is
concomitant with a 50% reduction in MMP activity
(Fig. 5b-bottom). Treatment of MDA-MB-231 with ALA +
TIMP-2 conditioned media also resulted in a >80% reduction
in invasiveness that is also accompanied by a >50% reduction
in MMP activity (Fig. 5).
proMMP-2 and proMMP-9 levels in T47D and MDA-MB-231
were not altered after treatment with either TIMP-2
or ALA + TIMP-2 conditioned media
Treatment with TIMP-2 or ALA + TIMP-2 conditioned
media did not significantly change the activation profiles
of pro-MMP-2 in T47D (Fig. 5c-top), nor pro-MMP-2 and
pro-MMP-9 in MDA-MB-231 cells (Fig. 5c-bottom). ProMMP-9 was detectable at very low levels, while levels of
pro-MMP-2 and -9 were comparable in MDA-MB-231cells
under all treatment conditions.

Discussion
Given the known benefits associated with elevated TIMP
levels in a number of cancers (Alakus et al. 2008; StetlerStevenson and Seo 2005; Svagzdys et al. 2011), it is disappointing that TIMP utilization as a therapeutic agent has
not been overly successful (Stetler-Stevenson 2008). Indeed, our examination of TIMP-2 expression in breast cancer using Kaplan-Meier analysis demonstrated that elevated
TIMP-2 levels are associated with higher overall and
metastasis-free survival. While elevated TIMP-2 levels
may be beneficial, the overall action of TIMP-2 is dependent on its ability to both inhibit MMPs with its N-terminal
domain, as well as interact with the cell surface with its Cterminal domain. As such, its specific actions will be dependent on both the makeup of the ECM environment as well as
the cell surface. Other research has shown that elevated
TIMPs are most beneficial when MMP levels are also high
(Alakus et al. 2008; Svagzdys et al. 2011).
In this study, low and high TIMP/MMP expressing cancer
cells were treated with TIMP-2 or ALA + TIMP-2
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conditioned media to further our understanding of the molecular mechanisms underlying TIMP-2 biology. Wild-type
TIMP-2 is both a direct inhibitor of MMP activity, and an
activator or pro-MMP-2 (with MMP-14), as well as a potential
ligand for cell surface receptors, such as α3β1 integrin, that
induce the upregulation of MMP suppressive proteins such as
RECK. By combining direct MMP inhibitory potential with
cell signaling activities TIMP-2 utilizes two complementary
mechanisms that provide for the negative regulation of MMP
activity, and concomitant decrease in cellular invasive potential. However, TIMP-2 can also participate in the activation of
MMPs, thereby potentiating MMP activity. Previous studies
have shown that TIMP-2 inhibits tumour growth and invasion
both in vivo and in vitro. However, these effects were obtained
with TIMP-2 levels ranging from 2.5 to 10 μg/ml which are
25 to 100-fold higher than found in normal tissues or biological fluids (10-100 ng/ml) (Larsen et al. 2005). In this study,
we treat breast cancer cells with TIMP-2/ALA + TIMP-2
conditioned media containing 22 ng/ml of the respective
proteins, a level well within and in the low end of physiological concentrations.
Surprisingly, when we assayed for the invasiveness of
MCF-7 cells treated with TIMP-2 conditioned media, we
saw a significant increase in the invasive nature of these cells.
Accordingly, we decided to look at additional cell lines to see
if this increased invasiveness in the presence of an MMP
inhibitor was a peculiarity of MCF-7 cells. We examined cells
that are both similar to, and different from, MCF-7 cells with
respect to characteristics crucial to this study. T47D cells, like
MCF-7 cells are regarded as less tumorigenic when compared
to MDA-MB-231 cells. Of importance to us is that both MCF7 and T47D cells show low levels of expression of TIMP-2,
MMP2 and many other MMPs (Balduyck et al. 2000;
Figueira et al. 2009; Jones et al. 2003). Further, MCF-7 and
T47D share similar invasive capabilities, and their invasive
capabilities mirror each other even when cells are treated with
extracellular reagents, such as the protein tenascin-C (Hancox
et al. 2009). These shared attributes of low MMP expression
levels and low invasiveness are not shared by MDA-MB-231
cells which express high levels of TIMPs and MMPs, and
whose invasive characteristics are also distinct (Balduyck et
al. 2000; Hancox et al. 2009; Jones et al. 2003).
Here we demonstrate that T47D cells, which are similar
to MCF-7 cells, also increased their invasiveness, though
not significantly, when treated with TIMP-2 conditioned
media. When we isolated media from these treated T47D
cells to assay for MMP activity, we saw that it was significantly increased in MMP activity. As MCF-7 and T47D
cells both have low endogenous levels of MMPs, we hypothesize that high levels of exogenous TIMP-2 works to
activate pro-MMPs when they are expressed at low levels
by these cell lines. Conversely, when we treated MDA-MB231 cells (which express high levels of active MMPs) with
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TIMP-2, this resulted in a significant decrease in both
MMP activity and invasiveness. Here addition of exogenous TIMP-2 inhibited the active MMPs that are already present at high levels. Gelatin zymography was
then used to examine the activation of specific MMPs.
However, it has been previously reported that gelatin
zymography is not sensitive enough to detect subtle
changes in proMMP-2 activation, especially in cell lines
that endogenously express low levels of TIMPs and
MMPs (Ratnikov et al. 2002). Indeed studies have published that proMMP-2 and -9 activity is not detectable
in MCF7 cell media using zymography (Ehrenfeld et al.
2011; Lauber and Gooderham 2011), while others demonstrate the contrary (Abdallah et al. 2007; Bartsch et
al. 2003). Similarly, zymography reports using conditioned media from T47D cells have conflicting results.
Some report the absence of pro-MMP-2 and -9 activity
(Janowska-Wieczorek et al. 2006) while others report
the presence (Abdallah et al. 2007). However, despite
differences in the absolute levels of pro-MMP-2 or -9 in
MCF-7, T47D or MDA-MB-231 media, these reports
agree on the relative differences between these cells
lines, with MDA-MB-231 showing the highest levels
of activity, and MCF-7 the lowest amongst these 3 cell
lines (Ehrenfeld et al. 2011; Janowska-Wieczorek et al.
2006; Jones et al. 2003). Here we demonstrate a TIMP2 dependent increase in global MMP activity that is not
detected through zymography. Given that other MMPs
in addition to MMPs 2 and 9 could be activated, and
with limitations and inconsistencies of zymography in
detecting subtle changes, other approaches need to be utilized
to understand how TIMP-2 is facilitating changes in cell
behavior.
To further investigate the nature of this phenomenon, we
used an ALA + TIMP-2 mutant that cannot inhibit MMP
activity (Wingfield et al. 1999). We found that treatment
with ALA + TIMP-2 conditioned media suppressed MMP
activity and invasiveness in both T47D and MDA-MB-231
cell lines. The reduction in MMP activity seen with ALA +
TIMP-2 is consistent with functions attributed to α3β1
integrin signaling that would still be possible through the
C-terminal domain of the ALA + TIMP-2 mutant, as the
upregulation of RECK mRNA occurs through TIMP-2 mediated α3β1 integrin signaling (Oh et al. 2004). However,
further investigation of the cell signaling cascades and
RECK regulation by cells is crucial to complete our understanding of TIMP biology.
Our assays using wild-type TIMP-2 and ALA +
TIMP-2 constructs allowed us to infer the relative importance of the MMP binding and cell signaling activities. Results indicated that the fully functional inhibitor
preferentially acts through direct MMP interaction, whether in
an inhibitory or activating context. Thus in an environments of
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low MMP activity, such as provided by MCF7 and T47D
cells, TIMP-2 predominantly activated pro-MMPs. In contrast, in an environment of high MMP activity, such as provided by MDA-MB-231 cells, TIMP-2 predominantly
inhibits MMP activity. When devoid of MMP binding potential (as is the ALA + TIMP-2 construct), TIMP-2 exclusively
suppresses MMP activity and invasiveness through cell signaling events, that include RECK, that are independent of the
cellular environment. These interactions are summarized in
Fig. 6.
Taken together, the relationship between the proteolytic
activity of a cell and its invasive character need to be
considered in a broader context. While proteolytic activity
and invasiveness are very strongly correlated, with highly
invasive cells often secreting many active MMPs, the
regulation of this activity is complex. Using the ALA +
TIMP-2 mutant we demonstrated that different cells
have specific abilities to utilize full-length TIMP-2. While
the addition of TIMP-2 can result in the inhibition of
metalloproteinase activity, this may be dependent on cell
type, endogenous MMP expression levels and likely
other factors. Our data suggests that TIMP-2 MMPindependent roles may be to exclusively down-regulate
invasiveness. Such exclusive down regulation of invasiveness could be potentially exploited in future therapeutics,
though more experimentation is needed to further elucidate
this complex phenomenon.

Fig. 6 Schematic model of TIMP-2’s biphasic effects on cellular
behavior. Regardless of cell type, the addition ALA + TIMP-2 conditioned media results in global MMP inhibition. This is likely achieved
by the upregulation of MMP inhibiting proteins such as RECK via
established MMP independent signaling pathways such as α3β1 integrins (middle path). Decreases in MMP activity is concomitant with
decreased cellular invasiveness. In non-invasive cell types that produce
relatively low levels of active MMPs, the addition of TIMP-2 facilitates MMP activation and provides a mechanism for these cells to
increases their cellular invasiveness. Conversely, highly invasive
MDA-MB-231 cells, which already produce high levels of active
MMPs, TIMP-2 inhibits MMP activity resulting in decreased invasiveness. CM; conditioned media
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